ST266—a next-generation anti-inflammatory and neuroprotective platform biologic

Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome of a novel population of cells derived from the amnion. The company is looking for partners to drive clinical drug development of its lead product in ophthalmological indications.

Like Comment
Page of
Go to the profile of Noveome Biotherapeutics

Noveome Biotherapeutics

Noveome is a clinical-stage biopharmaceutical company advancing ST266— a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. ST266 contains physiologic levels of hundreds of active biomolecules, including growth factors and cytokines. These molecules modulate a host of biological pathways, including anti-inflammatory and neuroprotective mechanisms, critical to healing.

No comments yet.